Search research articles
Contact Us
Filters
Showing results (71-80 of 122) with videos related to
Page
of 13
Sort By:
Haematologica
|
September 21, 2023
Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation
Sergiu Pasca, Saurav D Haldar, Alexander Ambinder, et al.
Blood Neoplasia
|
September 15, 2025
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2005
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia
Scott H Kaufmann, Judith E Karp, Louis Letendre, et al.
Biology
|
April 3, 2021
<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
Andrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
Leukemia Research
|
July 1, 2019
Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction
Bryan C Hambley, Kelly J Norsworthy, Jagar Jasem, et al.
Leukemia Research
|
September 5, 2017
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature
Kelly J Norsworthy, Amy E DeZern, Hua-Ling Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 2, 2019
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide
Shannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Research Square
|
November 24, 2025
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML
Theodoros Karantanos, Nour Naji, Taha Ahmedna, et al.
Blood Advances
|
August 20, 2020
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults
Heather J Symons, Marianna Zahurak, Yilin Cao, et al.
The Journal of Clinical Investigation
|
September 13, 2022
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia
Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 122) with videos related to
Sort By:
Page
of 13
Haematologica
|
September 21, 2023
Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation
Sergiu Pasca, Saurav D Haldar, Alexander Ambinder, et al.
Blood Neoplasia
|
September 15, 2025
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2005
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia
Scott H Kaufmann, Judith E Karp, Louis Letendre, et al.
Biology
|
April 3, 2021
<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
Andrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
Leukemia Research
|
July 1, 2019
Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction
Bryan C Hambley, Kelly J Norsworthy, Jagar Jasem, et al.
Leukemia Research
|
September 5, 2017
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature
Kelly J Norsworthy, Amy E DeZern, Hua-Ling Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 2, 2019
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide
Shannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Research Square
|
November 24, 2025
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML
Theodoros Karantanos, Nour Naji, Taha Ahmedna, et al.
Blood Advances
|
August 20, 2020
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults
Heather J Symons, Marianna Zahurak, Yilin Cao, et al.
The Journal of Clinical Investigation
|
September 13, 2022
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia
Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, et al.
Page
of 13